Deciphering the mechanisms of environmentally mediated Alectinib resistance in ALK plus NSCLC

被引：0
|
作者：
Kumar, Pragya
Turati, Virginia
Marusyk, Andriy
机构：
来源：
CANCER RESEARCH | 2022年 / 82卷 / 10期
关键词：
D O I：
10.1158/1538-7445.EVODYN22-B032
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B032
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Phase 2 Study of Ceritinib in Patients with ALK plus NSCLC with Prior Alectinib Treatment in Japan: ASCEND-9
    Horinouchi, H.
    Maemondo, M.
    Hida, T.
    Takeda, M.
    Hotta, K.
    Hirai, F.
    Kim, Y.
    Matsumoto, S.
    Mitsudomi, T.
    Seto, T.
    Moizumi, S.
    Tokushige, K.
    Hatano, B.
    Nishio, M.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1951 - S1952
  • [42] Genomic heterogeneity of ALK rearrangements and acquired resistance pathways in ALK plus Advanced non-small cell lung cancer (NSCLC) treated with upfront alectinib: Preliminary results of GALILEO project
    Vita, E.
    Monaca, F.
    Russo, J.
    Stefani, A.
    Zhang, Q.
    Di Salvatore, M.
    Trisolini, R.
    Lococo, F.
    Cancellieri, A.
    Tortora, G.
    Bria, E.
    ANNALS OF ONCOLOGY, 2023, 34
  • [43] Activity of Brigatinib in the Setting of Alectinib Resistance Mediated by ALK I1171S in ALK-Rearranged Lung Cancer
    Sehgal, Kartik
    Peters, Mary Linton B.
    VanderLaan, Paul A.
    Rangachari, Deepa
    Kobayashi, Susumu S.
    Costa, Daniel B.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (01) : E1 - E3
  • [44] The cost-effectiveness of alectinib in anaplastic lymphoma kinase-positive (ALK plus ) advanced NSCLC previously treated with crizotinib
    Carlson, Josh John
    Wong, William Bruce
    Canestaro, William
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [45] ALKTERNATE: A Pilot Study Alternating Lorlatinib with Crizotinib in Patients with ALK plus NSCLC and ALK-inhibitor Resistance
    Itchins, M.
    Liang, S.
    Brown, C.
    Barnes, T.
    Marx, G.
    Chin, V.
    Kao, S.
    Yip, P. Y.
    Mersiades, A. J.
    Nagrial, A.
    Bray, V.
    Peters, G.
    Parakh, S.
    John, T.
    Li, M.
    Li, B. T.
    McKay, M.
    Molloy, M.
    O'Byrne, K.
    Lee, C.
    Gill, A.
    Solomon, B. J.
    Pavlakis, N.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S351 - S352
  • [46] CNS efficacy results from the phase III ALUR study of alectinib vs chemotherapy in previously treated ALK plus NSCLC
    de Castro, J.
    Novello, S.
    Mazieres, J.
    Oh, I-J.
    Migliorino, M. R.
    Helland, A.
    Dziadziuszko, R.
    Griesinger, F.
    de Marinis, F.
    Zeaiter, A.
    Cardona, A.
    Balas, B.
    Johannsdottir, H.
    Chlistalla, M.
    Smoljanovic, V.
    Wolf, J.
    ANNALS OF ONCOLOGY, 2017, 28
  • [47] Comparative Efficacy of First-Line Ceritinib at a Dose of 450mg with Food and Alectinib in Advanced ALK plus NSCLC
    Liang, F.
    Shen, D.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S1032 - S1032
  • [48] Impact of the EML4-ALK variant on the efficacy of alectinib (ALC) in untreated ALK plus advanced NSCLC (aNSCLC) in the global phase III ALEX study
    Dziadziuszko, R.
    Mok, T. S.
    Camidge, D. R.
    Shaw, A. T.
    Noe, J.
    Nowicka, M.
    Liu, T.
    Mitry, E.
    Peters, S.
    ANNALS OF ONCOLOGY, 2018, 29
  • [49] Comparative efficacy of first-line ceritinib and alectinib in advanced ALK plus NSCLC: A cross-study indirect comparison
    Chan, C. P. K.
    Li, J.
    Knoll, S.
    Tang, W.
    Bocharova, I.
    Signorovitch, J.
    ANNALS OF ONCOLOGY, 2018, 29
  • [50] The cost-effectiveness of alectinib in anaplastic lymphoma kinase-positive (ALK plus ) advanced NSCLC previously treated with crizotinib
    Carlson, J. J.
    Canestaro, W.
    Ravelo, A.
    Wong, W.
    JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (07) : 671 - 677
12345